{"id":"https://genegraph.clinicalgenome.org/r/6ca55e1a-6ddd-4448-9bb6-a60d8f8da1abv1.0","type":"EvidenceStrengthAssertion","dc:description":"ATP7A encodes the copper-transporting ATPase alpha. In basal conditions, it is in the trans-Golgi Network (TGV) and transports copper to the cuproenzymes (copper metalloenzymes). However, in elevated copper concentrations, it localizes to the plasma membrane and facilitates the export of excess copper from the cells through exocytosis (MÃ¸ller et al., PMID: 19501626).\nThe gene was first mapped to chrXq13.3 in 1993 (Vulpe et al, PMID: 8490659; Mercer et al., PMID: 8490647; Chelly et al., PMID: 8490646) in patients with Menkes disease (MIM:309400) due to a loss of function mechanism in ATP7A. Partial loss of function is associated with occipital horn syndrome (MIM: 304150). Subnormal serum copper levels and early age of onset are characteristic for both phenotypes. In 2009, ATP7A was first reported in relation to X-linked recessive distal spinal muscular atrophy in two families (Kennerson et al., PMID: 20170900). These patients present during adulthood with progressive distal muscle weakness and atrophy without clinical or biochemical characteristics of systemic copper deficiency. Some patients show dysautonomic features (Gualandi et al., PMID: 31558336; Fradin et al., PMID: 33137485).\nPer criteria outlined by the ClinGen Lumping and Splitting Working group, we found a difference in molecular mechanism and phenotypic variability but no difference in inheritance pattern in the association of ATP7A with distal spinal muscular atrophy. Therefore, the following diseases entities have been split into the three before-mentioned entities: Menkes disease, Occipital Horn Syndrome and distal spinal muscular atrophy.\nFour different missense variants were reported of which three segregated in families (Kennerson et al., PMID: 20170900; Gualandi et al., PMID: 31558336) and one was sporadic (Fradin et al., PMID: 33137485). Two of these variants occur in the carboxyl half of the ATP7A protein, are highly conserved and absent in control populations (Kennerson et al., PMID: 20170900). Two other variants were predicted to be deleterious in in silico evaluations and were absent in control populations (Gualandi et al., PMID: 31558336; Fradin et al., PMID: 33137485).\nThe gene-disease association is also supported by experimental evidence. Patient (Atp7A-T994I)-derived fibroblasts show reduced trans-Golgi-localization of ATP7A and more diffuse signals in cultured cells. Immunoprecipitation assays identified p97/VCP as an interaction protein  (Yi et al., PMID: 22210628). Two mouse models were generated, a knock-in mouse (Atp7a-T994I) and a transgenic mouse (Atp7aMN/Y), with contradictory results. Herein the knock-in model showed no altered motor abilities or histological manifestations of acute or chronic neuropathy (Perez-Siles et al., PMID: 27293072), whereas the transgenic model exhibited progressive motor abnormalities and age-dependent loss of motor neuron cell bodies and denervation of the neuromuscular junction (Hodgkinson et al., PMID: 25639447).\nThe mechanism of pathogenicity appears to be partial loss of function, altered protein-to-protein interaction (cfr. P97/VCP), and intracellular trafficking.\nIn summary, ATP7A is moderately associated with x-linked distal spinal muscular atrophy. While more evidence is needed to establish this relationship definitely, no convincing contradictory evidence has emerged.\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/6ca55e1a-6ddd-4448-9bb6-a60d8f8da1ab","GCISnapshot":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10063","date":"2023-01-10T18:06:31.668Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10063","date":"2023-01-10T17:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0a0ae210-ee85-4101-9213-cd94d03709a4","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/02f1aafa-5c73-4d07-abc5-c5c94854aa4c","type":"Finding","dc:description":"motor neurons degeneration","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25639447","rdfs:label":"Atp7aMN/Ymice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5ee060b2-2a7e-4392-8903-e868bd52f756","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/08d59d62-591b-487b-9626-1e27d3f7968b","type":"FunctionalAlteration","dc:description":"mutant  ATP7As  did  not  clearlyco-localize  in  the  endoplasmic  reticulum,  early  or late  endo-somes,  lysosomes  or  endocytic  vesicles","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22210628","rdfs:label":"immunohistochemistry"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/510bb72f-82f5-47ac-b149-f97e7295410e","type":"EvidenceLine","dc:description":"no altered function demonstrated","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d768d8a3-5606-4ed5-8fea-d40613ea4e57","type":"FunctionalAlteration","dc:description":"no evidence for altered function","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22210628","rdfs:label":"yeast complementation assay"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ac74e375-851d-4796-8af5-2acb7f0924cf","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ba9d66f0-456a-4d9f-8c9b-1518ef0bea62","type":"FunctionalAlteration","dc:description":"In  cells  transfected  with  the  wild-typeallele,  ATP7A  moved  from  the  TGN  to  the  PM  in  200mMCu  (A),  whereas  in  cells  transfected  with  the  mutant  alleles,  the  ATP7A  signal  was  alreadylocated  predominantly  at  the  PM  under  basal  (0.5mMCu)  copper  conditions  (b  and  c).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22210628","rdfs:label":"immunohistochemistry in HEK cells transfected with mutant"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ea44ff10-a141-4d01-9da0-6232a6424d50","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/05d7b80c-a690-4605-9482-92cca1bf05fb","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22210628","rdfs:label":"immunoprecipitation","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ffb82f26-835a-478b-84bc-d93e3dc60b4a","type":"EvidenceLine","dc:description":"no altered expression demonstrated","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a9ce7bf-c06b-463a-bc8d-240e60b4983a","type":"Finding","dc:description":"no evidence for altered expression ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22210628","rdfs:label":"protein expression in patient derived fibroblasts","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d1e8ca4-1246-4e01-83a1-d1df0a13cd03","type":"EvidenceLine","dc:description":"Some evidence of gene impact","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d1e8ca4-1246-4e01-83a1-d1df0a13cd03_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20170900","allele":{"id":"https://genegraph.clinicalgenome.org/r/a8ec6e62-b1f7-4dbe-a594-1864d31cbdac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000052.7(ATP7A):c.4156C>T (p.Pro1386Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA256077"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/fe220e1d-40e5-41e1-b69f-8891342d3840","type":"EvidenceLine","dc:description":" some evidence of gene impact","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fe220e1d-40e5-41e1-b69f-8891342d3840_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33137485","allele":{"id":"https://genegraph.clinicalgenome.org/r/0416f346-85b6-41ff-bbd7-bb29d20d6c9d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000052.7(ATP7A):c.2576A>G (p.Asp859Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/929465"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6330fcc4-69e4-445d-bc22-222866d69478","type":"EvidenceLine","dc:description":" some evidence of gene impact","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6330fcc4-69e4-445d-bc22-222866d69478_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14985388","allele":{"id":"https://genegraph.clinicalgenome.org/r/15783c2d-376a-4978-9b53-01add901a192","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000052.7(ATP7A):c.2981C>T (p.Thr994Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA256075"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/45eef093-ed61-4f34-a802-f225464eebd0","type":"EvidenceLine","dc:description":" some evidence of gene impact","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/45eef093-ed61-4f34-a802-f225464eebd0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31558336","allele":{"id":"https://genegraph.clinicalgenome.org/r/7ea449e0-a9e5-4f2d-90b9-c1d70bde4c86","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000052.7(ATP7A):c.2972C>A (p.Ala991Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/549669"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/ec7c42f3-3cad-4020-aa75-cf103c5381ba_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6a52b5ef-8ba8-4d60-8986-5990fd4daa06_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14985388","rdfs:label":"Takata family (Family B in Kennerson 2010)","estimatedLodScore":3.01,"family":{"id":"https://genegraph.clinicalgenome.org/r/6a52b5ef-8ba8-4d60-8986-5990fd4daa06","type":"Family","rdfs:label":"Takata family (Family B in Kennerson 2010)","ethnicity":{"id":"cg:HispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/91a06bde-4a18-4d08-8240-c7e09060b966","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14985388","rdfs:label":"IV-36","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/15783c2d-376a-4978-9b53-01add901a192"},"detectionMethod":"Linkage analysis with 48 microsatellite markers from the human chromosome, spaced at approximately 5 cM, were selected from the ABI Prism Linkage Mapping sets(Applied Biosystems, Foster City, CA, USA). Analysis was performed for 30 genotyped family members: 10 affected male patients, 6 normal men, 11 obligate carriers, and 3 normal women (fig 2). These microsatellite markers were amplified by PCR and separatedby electrophoresis in a capillary system containing polymer 4 (POP04) in an ABI310 automated DNA sequencer. For the fine mapping of the region, based on two informative recombinant events (individuals IV-9 and IV-48, figs 1 and 2), nine microsatellite markers between DXS1216 and DXS1196 were selected, aplified by PCR and separated by gel electrophoresis; Two-point lod score linkage analysis between a putativedisease locus and each marker were calculated, under theassumption of X linked recessive inheritance, with a genefrequency of 0.00001 and equal male and female recombina-tion values","ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Genotyping","previousTesting":true,"previousTestingDescription":"spinal bulbarmuscular atrophy and X linked Charcot-Marie-Tooth as candidate genes","secondTestingMethod":"PCR","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6330fcc4-69e4-445d-bc22-222866d69478_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"large clinical variability, slow disease progression with indipendent gait till late in life. CMAP amplitude was reduced in seven patients and motorconduction velocity was slightly reduced in five. Sensory nerve conduction was always normal. Electromyography disclosed chronic denervation in seven patients.\nIn two young individuals (IV-11 and IV-52), neurophysiological evaluation was normal. Serum creatine kinase, tested in two patients (IV-36 and IV-48), was in the normal range.Nerve biopsy, performed in patient IV-45, was normal, while muscle histopathology for the proband showed a neurogenic pattern","phenotypePositiveAllelePositive":21,"phenotypes":["obo:HP_0009053","obo:HP_0002317","obo:HP_0008124","obo:HP_0001761","obo:HP_0008944","obo:HP_0007149"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/91a06bde-4a18-4d08-8240-c7e09060b966"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/3e9a53c4-eda7-4743-a9db-17c2a0fd240e_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20170900","rdfs:label":"Family A (Kennerson)","estimatedLodScore":3.01,"family":{"id":"https://genegraph.clinicalgenome.org/r/3e9a53c4-eda7-4743-a9db-17c2a0fd240e","type":"Family","rdfs:label":"Family A (Kennerson)","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/3ef3c09b-e21c-4b5f-acef-e782b3bccc4a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20170900","rdfs:label":"IV-5","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":13,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a8ec6e62-b1f7-4dbe-a594-1864d31cbdac"},"detectionMethod":"from previous paper, microsatellite markers DXS991, DXS1275, DXS8052, DXS559, DXS8046, DXS986, DXS6793, DXS995, DXS8076, DXS8114, DXS6803, DXS1196, DXS1217, and DXS990 were genotyped in the family. Mutation analysis was performed using high resolution melt protocols. PCR amplicons for mutation scanning were designed to cover the coding exons and flank-ing intronic sequences.","firstTestingMethod":"PCR","previousTesting":true,"previousTestingDescription":"GJB1 gene promoter analysis","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9d1e8ca4-1246-4e01-83a1-d1df0a13cd03_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"sex-linked distal weakness that begins in late childhood to early adulthood and is slowly progressive; normal early developmental milestones; sensory examination minimally abnormal, with mild reduction in vibratory sense at toes. Normal examination in female carriers. The electromyogram showed increased insertional activity, with positive waves and fibrillations in selected distal arm and leg muscles. Reduced CMAP, normal conduction velocities","phenotypePositiveAllelePositive":16,"phenotypes":["obo:HP_0008959","obo:HP_0003474","obo:HP_0009053","obo:HP_0002317","obo:HP_0003376"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/3ef3c09b-e21c-4b5f-acef-e782b3bccc4a"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/b73ea486-4791-43a0-b443-d9855622aa57_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31558336","rdfs:label":"Gualandi family","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/b73ea486-4791-43a0-b443-d9855622aa57","type":"Family","rdfs:label":"Gualandi family","ethnicity":{"id":"cg:HispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/8419a4e0-38b5-44d7-9a13-1d9251b16625","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31558336","rdfs:label":"PT1 and PT2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":27,"allele":{"id":"https://genegraph.clinicalgenome.org/r/7ea449e0-a9e5-4f2d-90b9-c1d70bde4c86"},"detectionMethod":"Next generation sequencing (NGS) was performed in all subjects using an in-house- designed lower motor neuron diseases gene panel. The panel includes 21 ALS, 12 SMA, 16 HMN and 14 CMT-associated genes ","ethnicity":{"id":"cg:HispanicOrLatino"},"firstTestingMethod":"Next generation sequencing panels","previousTesting":false,"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/45eef093-ed61-4f34-a802-f225464eebd0_variant_evidence_item"}}},"phenotypeFreeText":"onset at  around 27 years, serum CPK levels constantly slightly elevated (300-400 U/L), small fiber neuropathy, nvolving A delta and C fibers, including cutaneous sympathetic cholinergic and adrenergic autonomic fibers. CMAPs were significantly reduced or absent in tibial and peroneal nerve, less in median nerve ","phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0002028","obo:HP_0001582","obo:HP_0010837","obo:HP_0012877","obo:HP_0002839","obo:HP_0008180","obo:HP_0008944","obo:HP_0001288","obo:HP_0011967","obo:HP_0007410","obo:HP_0009053","obo:HP_0003438","obo:HP_0000929","obo:HP_0003394"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/8419a4e0-38b5-44d7-9a13-1d9251b16625"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3.5}],"evidenceStrength":"Moderate","sequence":5759,"specifiedBy":"GeneValidityCriteria9","strengthScore":7.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/LYDgTi6P0I4","type":"GeneValidityProposition","disease":"obo:MONDO_0010338","gene":"hgnc:869","modeOfInheritance":"obo:HP_0001417"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_ec7c42f3-3cad-4020-aa75-cf103c5381ba-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}